|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/20 | (2006.01) |
| A61K 9/2866 | (2013.01) | ||
| A61K 31/4162 | (2006.01) | ||
| A61K 31/4162 | (2013.01) | ||
| A61P 3/10 | (2006.01) | ||
| A61K 9/2018 | (2013.01) | ||
| A61K 9/28 | (2006.01) | ||
| A61P 3/10 | (2018.01) |
| (11) | Patento numeris | 3038465 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14840833.9 |
| Europos patento paraiškos padavimo data | 2014-08-25 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-07-06 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-10-06 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2014/052451 |
| Data | 2014-08-25 |
| (87) | Numeris | WO 2015/031228 |
| Data | 2015-03-05 |
| (30) | Numeris | Data | Šalis |
| 201361871951 P | 2013-08-30 | US |
| (72) |
COOPER, Vincent, Brett , GB
BRADLEY, Kathryn, Alanna , GB
PYGALL, Samuel, Robert , GB
GUPTA, Rajan , US
STANFORD, Madison, Paige , US
XIE, Lin , US
|
| (73) |
Merck Sharp & Dohme Corp. ,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
Merck Sharp & Dohme Limited , Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, GB |
| (54) | ORAL PHARMACEUTICAL FORMULATION OF OMARIGLIPTIN |
| ORAL PHARMACEUTICAL FORMULATION OF OMARIGLIPTIN |